Dariohealth CORP 10-Q quarterly reports

DarioHealth Corp. announced its second-quarter 2026 financial results, showing a decrease in total revenues and a continued net loss, though operating expenses were reduced.

DarioHealth Corp. reported a 17.3% decrease in revenue for the first quarter of 2026 compared to the prior year, primarily due to a non-recurring pharmaceutical partner revenue in the previous period.

DarioHealth Corp. reported a 32.5% revenue decrease in Q3 2025, alongside a reduced net loss and an ongoing strategic review to maximize shareholder value.

DarioHealth Corp. refinanced its debt facility and reduced operating expenses in Q2 2025, but reported increased net losses attributable to common shareholders and faces substantial doubt about its ability to continue as a going concern.

DarioHealth Corp. announces a 17.3% increase in revenue for Q1 2025, driven by commercial channel growth, alongside strategic debt refinancing and new partnerships aimed at expanding its B2B2C strategy.

DarioHealth Corp. saw a significant increase in revenue for Q3 2024, driven by growth in its commercial channel and the acquisition of Twill, despite ongoing losses and concerns about its ability to continue as a going concern.

DarioHealth Corp.'s Q2 2024 results show a mixed picture with revenue growth offset by increased expenses and a significant workforce reduction, alongside the integration of Twill.

DarioHealth Corp. reported a net loss of $7.175 million for the first quarter of 2024, which includes the acquisition of Twill, impacting revenue and expenses.